default author photo

Anna Spreafico

University of Toronto - Princess Margaret Cancer Centre

SCHOLARLY PAPERS

4

DOWNLOADS

222

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Refining TNM Classification for HPV-Mediated Oropharyngeal Carcinoma by the International Collaboration of Oropharyngeal Cancer Network (ICON-N-HPV ): A Multi-Center Cohort Study

Number of pages: 35 Posted: 31 Aug 2023
University of Toronto - Department of Radiation Oncology, University of Toronto - Department of Biostatistics, Cleveland Clinic - Department of Radiation Oncology, Mayo Clinic - Department of Radiation Oncology, Maastricht University - Department of Radiation Oncology (MAASTRO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Cleveland Clinic - Imaging Institute, Cleveland Clinic - Imaging Institute, Cleveland Clinic - Department of Radiation Oncology, Cleveland Clinic - Department of Radiation Oncology, Mayo Clinic - Department of Radiology, Mayo Clinic - Department of Radiation Oncology, Mayo Clinic Hospital - Phoenix - Department of Otolaryngology-Head and Neck Surgery, Maastricht University - Department of Radiology and Nuclear Medicine, Maastricht University - Department of Radiology and Nuclear Medicine, Maastricht University - GROW School for Oncology and Developmental Biology, Creighton University - Department of Surgery, Memorial Sloan Kettering Cancer Center, University of Toronto - Department of Biostatistics and University of Toronto
Downloads 127

Abstract:

Loading...

Human Papillomavirus, Oropharyngeal Cancer, Clinical N Classification, Extranodal Extension, Overall Survival

2.

A Phase Ii, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair–Proficient Colorectal or Pancreatic Cancer

Number of pages: 54 Posted: 14 Mar 2024
Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), Ontario Institute for Cancer Research, Ontario Institute for Cancer Research, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Tumor Immunotherapy Program, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre and University of Toronto - Princess Margaret Cancer Centre
Downloads 45

Abstract:

Loading...

Immunotherapy, biomarkers, colorectal, pancreatic, cancer, cold tumors

3.

Detection of Oligometastases in Patient with Oropharyngeal Carcinoma Following Definitive (Chemo)Radiotherapy

Number of pages: 34 Posted: 07 Oct 2024
South Western Sydney Local Health District - Liverpool Hospital, Princess Margaret Hospital, University of Toronto - Department of Biostatistics, University of Toronto - University Health Network, University of Toronto - University Health Network, University of Toronto - University Health Network, University of Toronto - University Health Network, Princess Margaret Hospital, Princess Margaret Hospital, University of Toronto, Princess Margaret Hospital, Princess Margaret Hospital, Princess Margaret Hospital, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Princess Margaret Hospital, Princess Margaret Hospital, Princess Margaret Hospital, University of Toronto - Department of Radiation Oncology and Princess Margaret Hospital
Downloads 27

Abstract:

Loading...

oligometastases, oropharyngeal cancer, surveillance imaging

4.

A First-in-Human Phase 1/2 Dose-Escalation Study of Mak683 (Eed Inhibitor) in Patients with Advanced Malignancies

Number of pages: 21 Posted: 09 Oct 2024
Gustave Roussy - Drug Development Department (DITEP), Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, affiliation not provided to SSRN, The Chinese University of Hong Kong (CUHK), Shizuoka Cancer Center, University of Cologne, University of Toronto - Princess Margaret Cancer Centre, Sarah Cannon Research Institute, affiliation not provided to SSRN, National Cancer Centre Singapore - Division of Medical Oncology, Humanitas University - Department of Biomedical Sciences, affiliation not provided to SSRN, National Hospital Organization Kyushu Cancer Center - Department of Hematology and Cell Therapy, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 23

Abstract:

Loading...

MAK683, EED, PRC2, DLBCL, ES, dose-escalation